SCHEDULE 13G: Biotechnology Value Fund Group Discloses 5.2% Passive Stake in Protagonist Therapeutics

A group of investment entities led by Biotechnology Value Fund L.P. and Mark N. Lampert has disclosed a collective 5.2% passive ownership stake in Protagonist Therapeutics, Inc.

Summary

• The filing is a Schedule 13G, indicating a passive beneficial ownership stake in Protagonist Therapeutics, Inc. (PTGX) by a group of investment entities.
• The reporting group includes Biotechnology Value Fund L.P., BVF I GP LLC, Biotechnology Value Fund II LP, BVF II GP LLC, Biotechnology Value Trading Fund OS LP, BVF Partners OS Ltd., BVF GP Holdings LLC, BVF Partners L.P., BVF Inc., and Mark N. Lampert.
• As of June 16, 2025, the aggregate amount beneficially owned by the group, primarily through BVF Partners L.P., BVF Inc., and Mark N. Lampert, is 3,211,041 shares of Protagonist Therapeutics' Common Stock.
• This ownership represents approximately 5.2% of the outstanding shares of Protagonist Therapeutics, Inc., based on 61,981,955 shares outstanding as of April 30, 2025.
• The filing explicitly states that the securities were not acquired and are not held for the purpose or with the effect of changing or influencing the control of the issuer, consistent with a passive investment strategy.

Sentiment

Score: 6

Explanation: The filing is largely neutral as a routine regulatory disclosure. However, the disclosure of a significant passive stake by a specialized biotechnology fund can be viewed as a moderately positive signal of investor confidence in the company's value.

Positives

• A significant passive stake by a specialized biotechnology investment fund like Biotechnology Value Fund L.P. may signal confidence in Protagonist Therapeutics' long-term prospects and valuation.

Future Outlook

The document does not contain any forward-looking statements or guidance from Protagonist Therapeutics, Inc. or the reporting persons regarding the company's future performance or strategic direction.

Industry Context

This filing represents a routine disclosure of a significant passive investment by a specialized biotechnology fund in a publicly traded biotechnology company. It indicates that the fund views Protagonist Therapeutics as a valuable investment, aligning with broader trends of institutional investors taking positions in promising biotech firms.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may provide a degree of confidence and stability to the shareholder base. No direct impact on other stakeholders (employees, customers, suppliers, creditors) is indicated by this ownership filing.

Key Dates

Recommendation

Keywords

Protagonist Therapeutics, Biotechnology Value Fund, SEC filing, Schedule 13G, passive investment, beneficial ownership, PTGX, institutional ownership